Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
Clinical trial NCT03403205 · TERMINATED
Trial details
- NCT number
- NCT03403205
- Sponsor
- Alexion Pharmaceuticals, Inc.
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-22
- Primary completion
- 2023-06-30
- Enrollment
- 214
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.